These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 7037164

  • 21. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE, Dreyer Z, Choi MR, Liang W, Skowronski R, Allamneni KP, Devidas M, Raetz EA, Adamson PC, Blaney SM, Loh ML, Hunger SP.
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [Abstract] [Full Text] [Related]

  • 22. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
    Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.
    Blood; 2013 Jul 25; 122(4):507-14. PubMed ID: 23741010
    [Abstract] [Full Text] [Related]

  • 23. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB.
    Lancet Oncol; 2015 Dec 25; 16(16):1677-90. PubMed ID: 26549586
    [Abstract] [Full Text] [Related]

  • 24. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
    Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K, Carlsen NT.
    Med Pediatr Oncol; 2002 May 25; 38(5):310-6. PubMed ID: 11979454
    [Abstract] [Full Text] [Related]

  • 25. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
    Willer A, Gerss J, König T, Franke D, Kühnel HJ, Henze G, von Stackelberg A, Möricke A, Schrappe M, Boos J, Lanvers-Kaminsky C.
    Blood; 2011 Nov 24; 118(22):5774-82. PubMed ID: 21940824
    [Abstract] [Full Text] [Related]

  • 26. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK, Schrøder H, Ingerslev J, Jakobsen P, Avramis VI, Müller HJ, Carlsen NT, Schmiegelow K.
    Br J Haematol; 2001 Dec 24; 115(4):983-90. PubMed ID: 11843837
    [Abstract] [Full Text] [Related]

  • 27. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
    Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ, Children's Oncology Study Group.
    J Pediatr Hematol Oncol; 2007 Sep 24; 29(9):627-32. PubMed ID: 17805038
    [Abstract] [Full Text] [Related]

  • 28. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
    Rizzari C, Zucchetti M, Conter V, Diomede L, Bruno A, Gavazzi L, Paganini M, Sparano P, Lo Nigro L, Aricò M, Milani M, D'Incalci M.
    Ann Oncol; 2000 Feb 24; 11(2):189-93. PubMed ID: 10761754
    [Abstract] [Full Text] [Related]

  • 29. Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
    Holland JF, Ohnuma T.
    Cancer Treat Rep; 1981 Feb 24; 65 Suppl 4():123-30. PubMed ID: 7049376
    [Abstract] [Full Text] [Related]

  • 30. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT, Harila-Saari A, Ruud E, Abrahamsson J, Pruunsild K, Vaitkeviciene G, Jónsson ÓG, Schmiegelow K, Heyman M, Schrøder H, Albertsen BK, Nordic Society of Paediatric Haematology and Oncology (NOPHO) group.
    Pediatr Blood Cancer; 2015 Mar 24; 62(3):427-33. PubMed ID: 25418987
    [Abstract] [Full Text] [Related]

  • 31. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP, Di Cataldo A, Ragusa R, Meli C, Lo Nigro L.
    J Clin Oncol; 1995 Feb 24; 13(2):339-44. PubMed ID: 7844595
    [Abstract] [Full Text] [Related]

  • 32. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
    Takahashi H, Koh K, Kato M, Isobe K, Yasui N, Mori M, Akiyama K, Kikuchi A, Hanada R.
    Rinsho Ketsueki; 2013 Apr 24; 54(4):370-7. PubMed ID: 23666219
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of dose and schedule of L-asparaginase in multidrug therapy of childhood leukemia.
    Sutow WW, George S, Lowman JT, Starling KA, Humphrey GB, Haggard ME, Vietti TJ.
    Med Pediatr Oncol; 1976 Apr 24; 2(4):387-95. PubMed ID: 1004382
    [Abstract] [Full Text] [Related]

  • 34. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL.
    Anticancer Res; 2007 Apr 24; 27(4C):2561-72. PubMed ID: 17695416
    [Abstract] [Full Text] [Related]

  • 35. [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].
    Rodriguez T, Baumgarten E, Fengler R, Soumpasis D, Henze G.
    Klin Padiatr; 1995 Apr 24; 207(4):207-10. PubMed ID: 7564153
    [Abstract] [Full Text] [Related]

  • 36. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
    Salzer W, Seibel N, Smith M.
    Expert Opin Biol Ther; 2012 Oct 24; 12(10):1407-14. PubMed ID: 22946493
    [Abstract] [Full Text] [Related]

  • 37. [Effect of L-asparaginase in small dosage on advanced leukemia in children (author's transl)].
    Kim P, Eto J, Fujimoto T, Sasaki Y, Hiyoshi Y, Yokoyama T, Ito M, Yanai M, Hasegawa K.
    Rinsho Ketsueki; 1980 Feb 24; 21(2):136-43. PubMed ID: 7411859
    [No Abstract] [Full Text] [Related]

  • 38. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
    Ogawa C, Taguchi F, Goto H, Koh K, Tomizawa D, Ohara A, Manabe A.
    Pediatr Blood Cancer; 2017 Sep 24; 64(9):. PubMed ID: 28244643
    [Abstract] [Full Text] [Related]

  • 39. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A, van Wering ER, Suciu S, Solbu G, van 't Veer MB, Rammeloo JA, de Koning J, van Zanen GE.
    Am J Pediatr Hematol Oncol; 1989 Sep 24; 11(2):125-33. PubMed ID: 2665546
    [Abstract] [Full Text] [Related]

  • 40. Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.
    Sassen SD, Mathôt RA, Pieters R, Kloos RQ, de Haas V, Kaspers GJ, van den Bos C, Tissing WJ, Te Loo M, Bierings MB, Kollen WJ, Zwaan CM, van der Sluis IM.
    Haematologica; 2017 Mar 24; 102(3):552-561. PubMed ID: 28250007
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.